Fusion Antibodies plc announces it will release its interim results for the six months ended 30 September 2018 on Monday, 26 November 2018.
Fusion Antibodies plc (AIM: FAB), a contract research organisation providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces it will release its interim results for the six months ended 30 September 2018 on Monday, 26 November 2018.
Enquiries:
| Fusion Antibodies plc | ||
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR | |
| James Fair, Chief Financial Officer | ||
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
| Virginia Bull / James Reeve / Asha Chotai | ||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 740 001 | |
| Paul McManus | Mob: +44 (0)7980 541 983 | |
